Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted

• Published in: European journal of pharmaceutical sciences Vol. 22; no. 5; pp. 419 - 425
• Main Authors: Yamanaka, Hiroyuki, Nakajima, Miki, Nishimura, Kiyoko, Yoshida, Ryoko, Fukami, Tatsuki, Katoh, Miki, Yokoi, Tsuyoshi
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier B.V 01.08.2004; Elsevier
• Subjects: Adult; Aryl Hydrocarbon Hydroxylases - deficiency; Aryl Hydrocarbon Hydroxylases - genetics; Aryl Hydrocarbon Hydroxylases - physiology; Biological and medical sciences; CYP2A6; Cytochrome P-450 CYP2A6; Female; Gene Deletion; General pharmacology; Humans; LC–MS/MS; Male; Medical sciences; Mixed Function Oxygenases - deficiency; Mixed Function Oxygenases - genetics; Mixed Function Oxygenases - physiology; Nicotine; Nicotine - administration & dosage; Nicotine - metabolism; Nicotine - urine; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; Poor metabolizer; CYP2A6; Poor metabolizer; LC–MS/MS; Nicotine; Human; LC-MS/MS; Alkaloid; Pharmaceutical technology; Gene; Pharmacokinetics; Metabolism

Generally, 70–80% of absorbed nicotine is mainly metabolized to cotinine by cytochrome P450 (CYP) 2A6. There is genetic polymorphism in the human CYP2A6 gene. Among several mutated alleles, CYP2A6*4 allele is a whole deleted type. The purpose of the present study was to clarify the metabolic profile...